Monopar Q2 net loss $2.2M ($0.16/shr); camsirubicin at 5th dose level

Monopar Therapeutics

Net loss of $2.2M ($0.16/shr) vs $2.8M ($0.22/shr) in Q2 2022.
Cash and short-term investments $10.2M; cash runway through Sep 2024; needs more capital within 12 mos.
Camsirubicin Phase 1b at 650 mg/m²; two patients showed 18% and 20% tumor reduction; no cardiotoxicity.
MNPR-101 radiopharma advancing toward first-in-human studies potentially by end of 2023.
R&D expenses decreased to $1.6M from $2.1M; G&A slightly up to $0.7M.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Monopar Therapeutics reported second quarter ended June 30, 2023 results: net income $2.2 million or $0.16 per share, EPS $0.16 per share.

Period: second quarter ended June 30, 2023
Net income: $2.2 million or $0.16 per share
EPS: $0.16 per share
Result: reported results

Exact text from the filing

Net loss for the second quarter of 2023 was $2.2 million or $0.16 per share compared to net loss of $2.8 million or $0.22 per share for the second quarter of 2022.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Monopar Therapeutics filing history →

Source: SEC EDGAR

accession 0001437749-23-022875

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.